Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders
Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders
复制标题
DOI：
10.1016/j.jneuroim.2020.577467
复制
发表时间：
2021-02-15
影响因子：
3.3
通讯作者：
Nakashima, Ichiro
中科院分区：
文献类型：
--
作者：
Akaishi, Tetsuya;Misu, Tatsuro;Nakashima, Ichiro
评估了抗髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）患者神经功能障碍的进展模式。每年对50例患者的408人-年进行神经功能障碍评估。超过30%的患者在前5年内有临床复发。未观察到独立于复发活动的残疾进展（PIRA），而在某些情况下，在临床发作后观察到逐步残疾进展。复发后残疾恶化的发生率高于发作后（P < 0.01）。与抗水通道蛋白-4抗体患者相似，MOGAD中典型的无PIRA的发作相关逐步残疾进展，表明预防复发的重要性。
The progression pattern of neurological disability among patients with anti-myelin oligodendrocyte glycopmtein antibody-associated disorders (MOGAD) was evaluated. Neurological disability was evaluated annually for 408 person-years in 50 patients. More than 30% of the patients had clinical relapses in the first 5 years. Disability progression independent of relapse activity (PIRA) was not seen, whereas a stepwise disability progression was observed after clinical attacks in some instances. Disability worsening was more frequent after relapses than after the onset episode (p < 0.01). Similar to patients with anti-aquaporin-4 antibodies, attack-related stepwise disability progression without PIRA is typical in MOGAD, suggesting the importance of relapse prevention.